TB-500 dosage and half-life, as the research actually records them

TB-500 Dosage in the Research Literature

TB-500 dosage in published research is recorded as a species-and-route figure, never as a human protocol. The figures below describe what was administered in studies; none is a recommendation, and most use full-length thymosin beta-4 rather than the TB-500 fragment. The single most useful thing to understand about TB-500 dosing is that there is no human dose for the fragment at all — every milligram figure below was given to an animal, or, in the one human study, was the parent protein.

Animal studies span a wide range. The rat embolic-stroke dose-response study administered intraperitoneal thymosin beta-4 at 2, 12, and 18 mg/kg, with a modeled optimal near 3.75 mg/kg ^[4]. Cardiac and neuro rodent work has used roughly 6–12 mg/kg ^[2][4]. That study is also the clearest dosing lesson in the literature, because it is non-monotonic: 2 and 12 mg/kg improved neurological outcomes while 18 mg/kg did not ^[4]. More was not better — a result that directly undercuts the community assumption that escalating to the highest tolerated amount maximizes benefit.

At the opposite extreme, picogram-to-nanogram amounts are bioactive in vitro: about 10 pg stimulated keratinocyte migration two-to-three-fold, and nanomolar concentrations activated hair-follicle stem cells ^[3][5]. The span from picograms in a dish to milligrams-per-kilogram in a rat is enormous, and it is one reason cross-context dose extrapolation for this molecule is unreliable.

Human dosing exists only for the parent protein. A randomized Phase 1 study gave synthetic thymosin beta-4 intravenously at 42, 140, 420, and 1260 mg — a single dose, then daily for 14 days — in healthy volunteers, and it was well tolerated across that range with no dose-limiting toxicities ^[6]. The non-clinical "loading then maintenance" schedules circulated in athletic communities are not derived from controlled human trials and have no published clinical validation ^[11]. The TB-500 dosage in research is, accordingly, a record of experiments rather than a guide to use.

Routes studied and stability

The routes in the literature track the model. Intraperitoneal injection predominates in rodent efficacy studies ^[4]; intravenous dosing carried the human Phase 1 of full-length Tβ4 and some cardiac models ^[6]; topical and ophthalmic delivery carried the corneal and dermal wound work and the dry-eye RCTs of the clinical-grade formulation ^[3][5]. Subcutaneous and intramuscular routes appear in community research use but not in controlled human efficacy trials. The route is not a detail: the FDA's stated safety concerns for this substance include potential immunogenicity for certain routes of administration, so the way a peptide is delivered changes the risk profile, not just the kinetics.

The material itself is supplied as a lyophilized powder for research use, reconstituted in bacteriostatic or sterile water and kept refrigerated. As a short acetylated peptide, TB-500 is more chemically robust than the full-length protein but is still subject to proteolysis and freeze-thaw degradation.

Identity and purity of research-grade material are recurring concerns ^[11] — and for this molecule the identity problem is specific and consequential. Because most efficacy data belong to full-length thymosin beta-4 (~4963 Da) while the marketed substance is the ~889 Da fragment, a sample whose true sequence or length is uncertain cannot be confidently mapped onto any published finding. A reader weighing the dose figures above should treat the fragment-versus-parent question as the first variable, ahead of the numbers themselves.

What is the half-life of TB-500?

No validated human pharmacokinetic half-life exists for the TB-500 heptapeptide. The honest answer to the TB-500 half-life question is that the fragment has not been characterized in a human PK study at all.

What exists is adjacent. In the intravenous Phase 1 study of full-length thymosin beta-4, pharmacokinetics were dose-proportional and the half-life increased with dose ^[6] — a property of the ~4963 Da protein, not the ~889 Da fragment. Separately, anti-doping LC-MS work characterizes TB-500 and its metabolites in equine plasma and urine, but that work is built for detection, not for establishing a therapeutic human half-life.

The distinction is not pedantic. A 43-residue protein and a 7-residue fragment have different sizes, different susceptibilities to proteolysis, and almost certainly different clearance — so the dose-proportional half-life observed for the parent protein cannot be assumed for the fragment. The community half-life figures that circulate for TB-500 are not traceable to a published human pharmacokinetic study of the heptapeptide, and this site does not restate them as if they were. Where a number cannot be sourced to a study, it is left off the record rather than borrowed.